➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKinsey
Baxter
Medtronic
Moodys

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 7,267,979

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,267,979
Title:Method of controlling gene silencing using site specific recombination
Abstract: This invention relates to methods of controlling gene silencing using site-specific recombination. A variety of constructs are provided which are useful for conditional or regulated gene silencing in plants, comprising a suite of constitutive, inducible, tissue-specific or developmental stage-specific promoters operably linked to target sequences (TS). Recombinase inversion or excision yields double-stranded TS RNA, which thereby functions to trigger endogenous gene silencing mechanisms. By matching promoters, responsive to various inducers, plant tissues or plant developmental states with the recombinase systems, transcriptional stop fragments or introns and target sequences, gene silencing of virtually any target sequence may be modulated at any plant development stage or in any plant generation. This is especially useful, when genes responsible for gene silencing are down-regulated to permit expression of particular transgenes at levels greater than permitted when gene silencing is activated.
Inventor(s): Yadav; Narendra S. (Chadds Ford, PA)
Assignee: Pioneer Hi-Bred International, Inc. (Johnston, IA)
Application Number:10/611,748
Patent Claims:see list of patent claims

Details for Patent 7,267,979

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Pioneer Hi-Bred International, Inc. (Johnston, IA) 2022-07-01 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Pioneer Hi-Bred International, Inc. (Johnston, IA) 2022-07-01 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Pioneer Hi-Bred International, Inc. (Johnston, IA) 2022-07-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.